吉非替尼治疗非小细胞肺癌药物经济学评价

doi:10.19739/j.cnki.issn1001-9510.2019.05.015

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (1002 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To make a pharmacoeconomic evaluation of gefitinib and carboplatin plus paclitaxel in treating non-small cell lung cancer considering the medical insurance management, and the whole society in Hubei province. Methods IPASS test Results were taken as the treatments utility evidence, corresponding medical expense by the survey in Wuhan five hospitals as the cost. Incremental cost-utility analysis was done by their Epidermal Growth Factor Receptor (EGFR) mutation. Results The incremental cost of the treated by gefitinib was 0.98 times to the per capital GDP by their overall survival (OS), 0.61 times to the per capital GDP by their quality of life adjusted OS in the EGFR positive group. The OS was lower treated by gefitinib than that of control group in the EGFR negative group. Conclusion Gefitinib met the recommended criteria for pharmacoeconomic evaluation to EGFR positive patients. It is suggested that gefitinib be included in medical insurance payments, and the EGFR mutation test was strongly recommended before they be treated with gefitinib.

Key words： Gefitinib Non-small cell lung cancer Pharmacoeconomic evaluation

Received: 27 February 2019

PACS:

R956

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Shengwen
	SU Jin
	DING Yuexia

Cite this article:

ZHAO Shengwen,SU Jin,DING Yuexia. Pharmacoeconomic evaluation of gefitinib in the treatment of non-small cell lung cancer[J]. 滨州医学院学报, 2019, 42(5): 373-376.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2019.05.015 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2019/V42/I5/373

[1] 潘睿. 中国慢性病前瞻性研究队列恶性肿瘤发病与死亡分析[D]. 南京:南京医科大学, 2017.
[2] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[3] 2015年湖北省肿瘤登记年报[R]. 武汉: 湖北省肿瘤登记中心, 2016.
[4] 中央经济工作会议在北京举行--时政--人民网[EB/OL].(2018/12/22)[2019/4/24]. http://politics.people.com.cn/n1/2018/1222/c1024-30481785.html.
[5] 17种抗癌药纳入乙类范围[J]. 中国人力资源社会保障, 2018(11):7.
[6] 国家人力资源和社会保障部. 人力资源社会保障部关于将36种药品纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的通知[EB/OL].(2017/07/18)[2019/3/28]. http://www.mohrss.gov.cn/gkml/zlbmxgwj/ylbx_3063/201707/t20170718_274153.html.
[7] 人社部发布医保药品目录准人谈判结果[J]. 中国医疗保险, 2017(8):6-7.
[8] 国家卫生计生委. 国家卫生计生委办公厅关于公布国家药品价格谈判结果的通知[EB/OL]. (2017/02/28)[2019/2/20]. http://www.nhfpc.gov.cn/yaozs/s7655/201605/58c5bc1ed0f14c75b8f15f1c149b35f4.shtml.
[9] 刘伟, 管晓东, 李虹耀, 等. 国外医疗保险药品谈判结果实施模式研究进展[J]. 中国药事, 2016, 30(1):1-7.
[10] Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma [J]. New Engl J Med, 2009, 361(10):947-957.
[11] 万崇华, 张灿珍, 宋元龙, 等. 肺癌患者生存质量测定量表FACT-L中文版[J]. 中国肿瘤, 2000(3):109-110.
[12] 中国药物经济学评价指南课题组, 刘国恩, 胡善联, 等. 中国药物经济学评价指南(2015版)[J]. 中国药物经济学, 2015(3):6-9.
[13] National Institute for Health Care Excellence. Guide to the Methods of Technology Appraisal 2013[M]. London: National Institute for Health and Care Excellence (NICE), 2013.